Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Dyadic Announces the Filing of Initial Form 10 Registration Statement with the SEC
BiotechnologyCompany Update

Dyadic Announces the Filing of Initial Form 10 Registration Statement with the SEC

November 5, 2018 8:30 AM

JUPITER, FL / ACCESSWIRE / November 5, 2018 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced that the Company has filed a Form 10 registration statement with the U.S. Securities and Exchange Commission...

Read more
Neocis Names Fred Moll, M.D. to Board of Directors
BiotechnologyCompany UpdateManagement Changes

Neocis Names Fred Moll, M.D. to Board of Directors

November 1, 2018 1:10 PM

MIAMI, FL / ACCESSWIRE / November 1, 2018 / Neocis, Inc., an innovator in dental implant surgery utilizing advanced robotics, announced today that Fred Moll, M.D. has joined its board of directors as of September 2018. ''Fred is a respected industry leader and an ideal fit for our board,'' said Alon Mozes, PhD, Chief Executive Officer. ''His impressive career has been dedicated to revolutionizing medicine. In the field of surgical robotics, he...

Read more
Positive Phase 3 Efficacy Data for Abicipar, Ongoing Clinical Trials for MP0250 In Oncology and Further Advancement of I/O Pipeline
BiotechnologyCompany Update

Positive Phase 3 Efficacy Data for Abicipar, Ongoing Clinical Trials for MP0250 In Oncology and Further Advancement of I/O Pipeline

November 1, 2018 2:00 AM

Research & Development: MP0250 in multiple myeloma: Clinical trial ongoing with dose set at 8mg/kg every 3 weeks in combination with bortezomib/dexamethasone. Durable responses were seen in patients who came from proteasome inhibitor (PI) based pretreatment, suggesting that MP0250 might be capable of reversing PI adaptive resistance MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC):...

Read more
INmune Bio to Present at National Investment Banking Association Conference
BiotechnologyConferences

INmune Bio to Present at National Investment Banking Association Conference

October 30, 2018 8:30 AM

LA JOLLA, CA / ACCESSWIRE / October 30, 2018 / INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer, today announced that RJ Tesi, M.D., CEO and President of the Company, will present a company overview at the upcoming National Investment Banking Association Conference, with details as follows: National Investment Banking Association 145th...

Read more
Abicipar Phase 3 Data Presented at AAO Conference in Chicago: Potential to be the First Fixed 12-week Anti-VEGF Therapeutic
BiotechnologyCompany UpdateConferences

Abicipar Phase 3 Data Presented at AAO Conference in Chicago: Potential to be the First Fixed 12-week Anti-VEGF Therapeutic

October 29, 2018 2:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 29, 2018 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced that the phase 3 safety and efficacy data of abicipar in patients with neovascular Age-related Macular Degeneration (nAMD) were presented at the American Academy of Ophthalmology (AAO) conference in Chicago. In two...

Read more
Viridium Reports Fiscal 2018 Third Quarter Results
Biotechnology

Viridium Reports Fiscal 2018 Third Quarter Results

October 24, 2018 8:10 PM

VANCOUVER, BC / ACCESSWIRE / October 24, 2018 / Viridium Pacific Group Ltd. ("Viridium" or the "Company") (TSX-V: VIR) (OTCPink: VIRFF) is pleased to announce its financial results for the third quarter of fiscal year 2018. The Company’s third quarter filings, including quarterly financial statements and "Management Discussion & Analysis" are now available on SEDAR (www.sedar.com). "Our third quarter was a strong push for us ahead of...

Read more
Dyadic to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018
BiotechnologyCompany UpdateEarnings

Dyadic to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018

October 24, 2018 4:30 PM

JUPITER, FL / ACCESSWIRE / October 24, 2018 / Dyadic International, Inc. (''Dyadic'') (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced that the Company will report its financial results for the quarter ended September 30, 2018 after the market...

Read more
Vitro BioPharma Engages Senior Director of Sales and Marketing
BiotechnologyManagement Changes

Vitro BioPharma Engages Senior Director of Sales and Marketing

October 23, 2018 1:40 PM

GOLDEN, CO / ACCESSWIRE / October 23, 2018 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro BioPharma, today announced the engagement of a senior Sales and Marketing Director. The company has engaged Keith V. Burge to be its full time Director of Sale and Marketing. Mr. Burge has a B.S. in biology and has extensive experience in building sales channels and providing market branding for new products going to market. He has an entrepreneurial...

Read more
Molecular Loop Acquires MIP-Based DNA Targeting Technology
BiotechnologyCompany Update

Molecular Loop Acquires MIP-Based DNA Targeting Technology

October 16, 2018 3:05 PM

Startup introduces streamlined, robust workflow for NGS sample preparation and analysis BOSTON, MA / ACCESSWIRE / October 16, 2018 / Molecular Loop Biosolutions LLC, a company specializing in advanced sample preparation solutions and data analysis for next-generation DNA sequencing, is pleased to announce the acquisition of Good Start Genetics' molecular inversion probe-based DNA targeting and analysis technology from Invitae Corporation. The...

Read more
Experion Receives License to Sell Starter Material
Biotechnology

Experion Receives License to Sell Starter Material

October 16, 2018 1:35 PM

VANCOUVER, BC / ACCESSWIRE / October 16, 2018 / Viridium Pacific Group Ltd. ("Viridium" or the "Company") (TSXV: VIR) (OTC PINK: VIRFF) is pleased to announce that its wholly owned subsidiary, Experion Biotechnologies Inc. ("Experion"), has received an amended license from Health Canada allowing for the sale of cannabis starter material, including cannabis seeds and live plants. This license permits Experion to distribute starter material to...

Read more
Mymetics Starts Research Collaboration Project in Cancer Immunotherapy with eTheRNA
BiotechnologyCompany Update

Mymetics Starts Research Collaboration Project in Cancer Immunotherapy with eTheRNA

October 16, 2018 2:00 AM

EPALINGES, SWITZERLAND / ACCESSWIRE / October 16, 2018 / Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines, announced today that Mymetics BV, the Dutch subsidiary of Mymetics Corporation, has entered into a research collaboration project with eTheRNA immunotherapy NV, a clinical stage biotech company developing novel mRNA cancer immunotherapies. The objective of the project is to...

Read more
Molecular Partners Invites Investors to Participate in its 2018 R&D Day
BiotechnologyConferences

Molecular Partners Invites Investors to Participate in its 2018 R&D Day

October 15, 2018 11:30 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 15, 2018 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics to treat serious diseases, is hosting its 2nd R&D update on "Building Tomorrow's Breakthroughs." When: Thursday, December 6, 2018 Check-In & Lunch 11:30am - 12:00pm ET Presentations and Q&A 12:00pm - 2:30pm ET Where: The Yale Club 50 Vanderbilt Avenue New...

Read more
Viridium Pacific Group Announces C$16 Million Private Placement Financing
Biotechnology

Viridium Pacific Group Announces C$16 Million Private Placement Financing

October 14, 2018 4:00 PM

VANCOUVER, BC / ACCESSWIRE / October 14, 2018 / Viridium Pacific Group Ltd. ("Viridium" or the "Company") (TSX-V: VIR) (OTC PINK: VIRFF) is proposing a common equity financing by way of a private placement of 17,582,418 units (the "Units") at a price of $0.91 per Unit (the "Offering Price") to raise aggregate gross proceeds to the Company of $16,000,000 Canadian dollars (the "Offering"). Under the terms of the financing, each Unit is comprised...

Read more
Sandesara Promoted Sterling Biotech Continues Advancing Loan Settlement Talks
BiotechnologyFinancing

Sandesara Promoted Sterling Biotech Continues Advancing Loan Settlement Talks

October 11, 2018 4:30 PM

MUMBAI, INDIA / ACCESSWIRE / October 11, 2018 / The representatives of Sterling Biotech are progressing discussions with the Committee of Creditors (CoC) to settle outstanding loans. Beginning June 11, 2018, the company was admitted for insolvency proceedings within the Corporate Insolvency Resolution Process (CIRP). The CoC'S legal representative states that funds have been deposited into an escrow account intended for settling dues following...

Read more
New Mymetics Data Regarding Cold Chain Independent Virosome Based Vaccines to be Presented at AAPS in Washington, D.C.
Biotechnology

New Mymetics Data Regarding Cold Chain Independent Virosome Based Vaccines to be Presented at AAPS in Washington, D.C.

October 11, 2018 9:35 AM

-Poster presentation showing retention of structural integrity and good immunogenicity of spray dried virosome-based vaccine stored at different temperatures and administered as a nasal powder -Poster presentation at AAPS - Washington, D.C., USA, Tuesday November 6th, 2018 EPALINGES, SWITZERLAND / ACCESSWIRE / October 11, 2018 / Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines...

Read more
Oncolix, Inc. Finalizes CycloSam(R) License Agreement For Osteosarcoma
BiotechnologyCompany UpdateInvestor RelationsMergers and AcquisitionsProduct Announcements

Oncolix, Inc. Finalizes CycloSam(R) License Agreement For Osteosarcoma

October 10, 2018 4:45 PM

HOUSTON, TX / ACCESSWIRE / October 10, 2018 / Oncolix, Inc. (OTCQB: ONCX) (the ''Company''), a biotechnology company focused on gynecological cancers, announced that the Company has finalized its license agreement from IGL Pharma, Inc., (''IGLP'') for a novel, clinical stage drug for the treatment of osteosarcoma. Other potential indications include bone metastases and bone marrow ablation. Highlights: License includes all uses for the...

Read more
Sandesara Promoted Sterling Biotech Limited to Settle Loans Outside IBC
BiotechnologyCompany Update

Sandesara Promoted Sterling Biotech Limited to Settle Loans Outside IBC

October 8, 2018 3:37 AM

Sandesara Aims at Settling Loans Outside IBC by Promoting Sterling Biotech Limited MUMBAI, INDIA / ACCESSWIRE / October 8, 2018 / Through its representatives, Sterling Biotech is currently in discussions with the Committee of Creditors (CoC) to settle outstanding loan amounts. On June 11, 2018, the company was admitted for insolvency proceedings under the Corporate Insolvency Resolution Process (CIRP). The CoC'S legal representative has stated...

Read more
Pressure BioSciences Accelerates Development of Novel Ultra Shear Technology Platform to Pursue Commercialization into Major New Markets
BiotechnologyInvestor Relations

Pressure BioSciences Accelerates Development of Novel Ultra Shear Technology Platform to Pursue Commercialization into Major New Markets

October 3, 2018 9:25 AM

Company's Commitment Includes Significant Buildout of Manufacturing Space, Accelerated Instrument & Applications Development, Staff Additions, New IP Development, and Expanded Partnership Negotiations SOUTH EASTON, MA / ACCESSWIRE / October 3, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology...

Read more
Dyadic International to Present Thursday October 4, 2018 at 2:30 p.m. at the  OTCQX(R) Virtual Investor Conference
BiotechnologyConferences

Dyadic International to Present Thursday October 4, 2018 at 2:30 p.m. at the OTCQX(R) Virtual Investor Conference

October 1, 2018 10:00 AM

JUPITER, FL / ACCESSWIRE / October 1, 2018 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, today announced that it will present Thursday October 4, 2018 at 2:30 p.m. at the OTCQX® Virtual Investor Conference...

Read more
Oncolix, Inc. Signs Letter of Intent to Enter into a License Agreement to Treat Osteosarcoma
Biotechnology

Oncolix, Inc. Signs Letter of Intent to Enter into a License Agreement to Treat Osteosarcoma

September 25, 2018 7:52 AM

HOUSTON, TX / ACCESSWIRE / September 25, 2018 / Oncolix, Inc. (OTCQB: ONCX) (the "Company"), a biotechnology company focused on gynecological cancers, announced that the Company has entered into a non-binding letter of intent for an exclusive worldwide license agreement from IGL Pharma, Inc., ("IGLP") for a novel drug for the potential treatment of osteosarcoma, bone metastases and bone marrow ablation. Highlights: Proposal includes all...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?